Capstone Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capstone Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$677K	Buy	7,458 +190	+3%	+$17.3K	0.02%	744
2017 Q1	$638K	Buy	7,268 +1,150	+19%	+$102K	0.02%	774
2016 Q4	$507K	Buy	6,118 +750	+14%	+$64.5K	0.01%	923
2016 Q3	$497K	Sell	5,368 -341	-6%	-$32.1K	0.01%	964
2016 Q2	$444K	Buy	5,709 +501	+10%	+$42.6K	0.01%	1009
2016 Q1	$430K	Buy	5,208 +230	+5%	+$18.7K	0.01%	1018
2015 Q4	$521K	Buy	4,978 +430	+9%	+$44.9K	0.02%	893
2015 Q3	$479K	Buy	4,548 +770	+20%	+$103K	0.01%	940
2015 Q2	$517K	Sell	3,778 -60	-2%	-$7.43K	0.01%	946
2015 Q1	$478K	Sell	3,838 -50	-1%	-$5.3K	0.01%	1108
2014 Q4	$351K	Sell	3,888 -210	-5%	-$17.5K	0.01%	1278
2014 Q3	$296K	Hold	4,098	–	–	0.01%	1366
2014 Q2	$255K	Sell	4,098 -1,465	-26%	-$88.5K	0.01%	1478
2014 Q1	$379K	Sell	5,563 -1,290	-19%	-$95.1K	0.01%	1265
2013 Q4	$482K	Sell	6,853 -8,272	-55%	-$562K	0.01%	1159
2013 Q3	$1.09M	Buy	15,125 +850	+6%	+$56.5K	0.03%	713
2013 Q2	$796K	Buy	+14,275	New	+$890K	0.02%	848

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Asset Management's BMRN Position: Q2 2017 in Review

Capstone Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 2.6% in Q2 2017, buying an estimated $17.3K and bringing the position to 7,458 shares worth $677K. The position accounts for 0.02% of the portfolio, ranked #744.

Capstone Asset Management first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $1.09M in Q3 2013. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Capstone Asset Management held 7,458 shares of BioMarin Pharmaceuticals worth $677K as of Q2 2017.
Capstone Asset Management bought 190 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $17.3K.
BioMarin Pharmaceuticals made up 0.02% of Capstone Asset Management's portfolio in Q2 2017, its #744 holding.
Capstone Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Capstone Asset Management's BioMarin Pharmaceuticals position peaked at $1.09M in Q3 2013.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.